# What Is KLOW Peptide? A Plain-English Overview | KLOW Doctor

> What is KLOW peptide? A co-formulated research blend of KPV, GHK-Cu, BPC-157 and TB-500 in one vial — 80 mg total, 50/10/10/10 split. No FDA approval. No controlled blend trial on record.

Co-formulation. Four constituents. No approved human use. No controlled blend study. Component IDs, roles and research context — logged here.

## TL;DR

KLOW peptide is not one molecule. It is four separate research peptides dissolved together in a single vial: KPV (an anti-inflammatory tripeptide), GHK-Cu (a copper-carrying tripeptide studied for skin and hair-follicle effects), BPC-157 (a 15-amino-acid peptide studied in wound and tendon models), and TB-500 (a short fragment of a protein called thymosin beta-4, studied for cell migration and tissue repair).

The standard research vial holds 80 mg total in a 50/10/10/10 split: 50 mg GHK-Cu, 10 mg each of BPC-157, TB-500, and KPV. GHK-Cu dominates by mass because it is the best-studied component for dermal and follicle applications.

Key facts: none of the four is FDA-approved for human use. The blend itself has never been tested in a controlled study. The four components clear the body at different speeds, which is a pharmacokinetic (how the body processes a drug) mismatch inherent to the co-formulation. TB-500 is on the WADA banned list for athletes.

## KLOW

KLOW is the trade name (and search term) for the four-peptide co-formulation. It is not an abbreviation — the name does not map to the constituent initials in a direct way. It distinguishes the blend from related research formulations:

- **GLOW**: the three-peptide version — GHK-Cu + BPC-157 + TB-500. No KPV. KLOW adds the KPV anti-inflammatory channel on top.
- **WOLVERINE**: a different multi-peptide blend with distinct composition.

KLOW is not a weight-management compound and is not related to GLP-1 / incretin signaling. None of its four constituents is a GLP-1 receptor agonist or an established metabolic weight-loss agent. The blend is studied in the context of soft-tissue repair, dermal biology, and inflammation — not metabolic or weight-management endpoints.

## KLOW peptide blend

The KLOW peptide blend is a co-formulation — multiple distinct compounds dissolved at fixed ratios in one vial. They remain separate molecules; they do not react with each other to form a new entity.

**Canonical composition (80 mg total):**

| Constituent | Mass | CAS | MW (Da) | Role |
|---|---|---|---|---|
| GHK-Cu | 50 mg | 89030-95-5 | 402.92 | Matrix, copper, hair-follicle |
| BPC-157 | 10 mg | 137525-51-0 | 1419.53 | Angiogenic, tissue-repair |
| TB-500 | 10 mg | — | 889.02 | Cytoskeletal, cell migration |
| KPV | 10 mg | 67727-97-3 | 342.44 | Anti-inflammatory, NF-kappaB |

GHK-Cu accounts for ~62.5% of vial mass and is the dominant component by quantity. No pharmacopeial or FDA-approved KLOW combination product exists.

## KLOW stack

Some researchers refer to the KLOW blend as a 'KLOW stack' — four peptides stacked in one vial rather than administered separately. This framing is informal and not a regulatory or scientific term.

The combination rationale is that the four constituents address consecutive or complementary steps in one tissue-repair cascade: KPV suppresses the initial cytokine surge (NF-kappaB/MAPK axis), GHK-Cu shifts fibroblast gene expression toward matrix rebuilding and provides copper for collagen crosslinking, BPC-157 drives angiogenesis via VEGFR2/PI3K/Akt/eNOS to re-vascularize damaged tissue, and TB-500 (via the LKKTET actin-binding motif, and more fully via native thymosin beta-4) accelerates keratinocyte migration and follicle stem-cell mobilization.

The cascade logic is mechanistically plausible but not directly validated: no controlled study has tested whether the four-component co-administration produces a different or superior outcome compared to any single component or any subset.

## What the literature attributes to each arm

**KPV (anti-inflammatory arm):** At nanomolar concentrations, KPV reduces NF-kappaB nuclear import and MAPK signaling in human intestinal epithelial cells and Jurkat T cells, lowers TNF-alpha / IL-6 / IL-1beta / IL-8 secretion, and reduces colitis severity in mice via the PepT1 transporter (Dalmasso 2008) [3].

**GHK-Cu (matrix and follicle arm):** Modulates ~31% of human genes at a ≥50%-change threshold (Pickart & Margolina 2018) [5]; increases collagen production with documented skin improvement in placebo-controlled topical trials; plasma GHK declines ~60% between age 20 and 60 (Pickart 2015) [4]; stimulates follicle activity in C3H mice (Trachy 1991) [9].

**BPC-157 (angiogenic arm):** Accelerates rat Achilles tendon healing at doses ranging from 10 picogram to 10 microgram per rat IP (Staresinic 2003) [2]; first-in-human IV safety pilot: n=2, up to 20 mg, well tolerated (Lee & Burgess 2025) [6].

**TB-500 / thymosin beta-4 (cytoskeletal and follicle-stem-cell arm):** +42% re-epithelialization at 4 days, +61% at 7 days (Malinda 1999) [1]; activates follicle bulge stem cells and raises MMP-2 (Philp 2004) [8]; stem-cell migration and differentiation pathway confirmed (Philp 2007) [12]. All follicle/re-epithelialization data are for full-length thymosin beta-4, not the TB-500 fragment.

---

Four channels logged, each cited to its own study — a research console, not a clinic.